This decrease in CRS severity observed with day 2 tocilizumab infusion after axi-cel is compatible with our observations, whereas the persistence in ICANS may be secondary to differences in the toxicity profile of CD3ζ-CD28 vs. CD3ζ-41BB CAR-T products. The gene discussed is CD28; the disease is congenital rubella syndrome.